LT3494115T - N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai - Google Patents

N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai

Info

Publication number
LT3494115T
LT3494115T LTEP17754889.8T LT17754889T LT3494115T LT 3494115 T LT3494115 T LT 3494115T LT 17754889 T LT17754889 T LT 17754889T LT 3494115 T LT3494115 T LT 3494115T
Authority
LT
Lithuania
Prior art keywords
bcl
inhibitors
benzamide derivatives
phenyl sulphonyl
sulphonyl
Prior art date
Application number
LTEP17754889.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Shaomeng Wang
Jianyong Chen
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of LT3494115T publication Critical patent/LT3494115T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
LTEP17754889.8T 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai LT3494115T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
LT3494115T true LT3494115T (lt) 2021-01-25

Family

ID=59677319

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17754889.8T LT3494115T (lt) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai

Country Status (27)

Country Link
US (3) US10829488B2 (OSRAM)
EP (3) EP3494115B1 (OSRAM)
JP (2) JP6651180B2 (OSRAM)
KR (2) KR102429704B1 (OSRAM)
CN (2) CN110483501B (OSRAM)
AU (2) AU2017305508B2 (OSRAM)
CA (1) CA3031419C (OSRAM)
CY (1) CY1123859T1 (OSRAM)
DK (1) DK3494115T3 (OSRAM)
ES (1) ES2849959T3 (OSRAM)
HR (1) HRP20202073T1 (OSRAM)
HU (1) HUE053414T2 (OSRAM)
IL (2) IL264059B (OSRAM)
LT (1) LT3494115T (OSRAM)
MX (2) MX381588B (OSRAM)
MY (1) MY199409A (OSRAM)
PE (1) PE20190711A1 (OSRAM)
PH (1) PH12019500231A1 (OSRAM)
PT (1) PT3494115T (OSRAM)
RS (1) RS61821B1 (OSRAM)
RU (2) RU2722560C1 (OSRAM)
SA (1) SA519401020B1 (OSRAM)
SG (2) SG10201913643YA (OSRAM)
SI (1) SI3494115T1 (OSRAM)
SM (1) SMT202100025T1 (OSRAM)
WO (1) WO2018027097A1 (OSRAM)
ZA (2) ZA201900240B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
LT3494115T (lt) * 2016-08-05 2021-01-25 The Regents Of The University Of Michigan N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
PT3612531T (pt) * 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Agentes indutores de apoptose
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
TWI752335B (zh) * 2018-07-31 2022-01-11 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途
UA125241C2 (uk) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
AU2019314819A1 (en) * 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN111214471B (zh) * 2018-11-23 2021-04-02 苏州亚盛药业有限公司 药物组合物及其用途
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
TW202114692A (zh) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 一種含有mTOR抑制劑的藥物組合及其應用
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
CN118542872A (zh) * 2019-12-04 2024-08-27 苏州亚盛药业有限公司 药物组合及其用途
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー, インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
WO2021175321A1 (en) 2020-03-06 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
US20230398110A1 (en) * 2020-08-21 2023-12-14 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN114073707A (zh) * 2020-08-21 2022-02-22 苏州亚盛药业有限公司 治疗系统性红斑狼疮的组合物和方法
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
US20250319183A1 (en) 2021-04-07 2025-10-16 David Avigan Compositions and methods for the treatment of cancer
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ(スーチョウ)カンパニー,リミティド 医薬組合せおよびその使用
KR20240135747A (ko) * 2021-12-06 2024-09-12 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 항-세포사멸 단백질 bcl-2 억제제, 약학적 조성물 및 이의 응용
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
WO2008030836A2 (en) 2006-09-05 2008-03-13 Abbott Laboratories Bcl inhibitors treating platelet excess
AU2007329458A1 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CA2744711C (en) 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
AU2010204555B2 (en) 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012517241A (ja) 2009-02-11 2012-08-02 アボット・ラボラトリーズ Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
MY165884A (en) 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
JP6960912B2 (ja) 2015-12-30 2021-11-05 デックスコム・インコーポレーテッド 感度プロファイルに基づく留置センサの工場校正または不完全校正のためのシステム及び方法
LT3494115T (lt) 2016-08-05 2021-01-25 The Regents Of The University Of Michigan N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai

Also Published As

Publication number Publication date
US20180354950A1 (en) 2018-12-13
AU2021202113B2 (en) 2022-08-18
AU2017305508B2 (en) 2021-01-07
RU2020114660A3 (OSRAM) 2020-09-15
SG11201900135YA (en) 2019-02-27
PT3494115T (pt) 2021-01-15
IL264059A (en) 2019-01-31
MX381588B (es) 2025-03-12
CN110483501A (zh) 2019-11-22
MY199409A (en) 2023-10-25
SG10201913643YA (en) 2020-03-30
RU2020134802A (ru) 2022-04-25
KR20190035710A (ko) 2019-04-03
US20190315739A1 (en) 2019-10-17
CY1123859T1 (el) 2022-05-27
ES2849959T3 (es) 2021-08-24
RU2020114660A (ru) 2020-06-19
IL282099B (en) 2022-03-01
NZ750100A (en) 2021-01-29
EP3569601A2 (en) 2019-11-20
KR20210107170A (ko) 2021-08-31
EP4129999A1 (en) 2023-02-08
CN109311871A (zh) 2019-02-05
EP3569601B1 (en) 2022-06-22
IL264059B (en) 2021-05-31
EP3494115A1 (en) 2019-06-12
IL282099A (en) 2021-05-31
EP3494115B1 (en) 2020-10-21
SA519401020B1 (ar) 2022-03-16
HRP20202073T1 (hr) 2021-02-19
US10221174B2 (en) 2019-03-05
RS61821B1 (sr) 2021-06-30
AU2021202113A1 (en) 2021-05-06
CA3031419C (en) 2021-08-24
JP2020007311A (ja) 2020-01-16
CA3031419A1 (en) 2018-02-08
CN110483501B (zh) 2022-07-01
US20210002277A1 (en) 2021-01-07
US11718613B2 (en) 2023-08-08
EP3569601A3 (en) 2019-11-27
CN109311871B (zh) 2020-02-28
DK3494115T3 (da) 2021-01-18
BR112019001666A2 (pt) 2019-05-28
PH12019500231A1 (en) 2019-07-29
ZA201900240B (en) 2020-05-27
RU2722560C1 (ru) 2020-06-01
HUE053414T2 (hu) 2021-06-28
MX2019001391A (es) 2019-06-06
US10829488B2 (en) 2020-11-10
SMT202100025T1 (it) 2021-03-15
WO2018027097A1 (en) 2018-02-08
JP6651180B2 (ja) 2020-02-19
PE20190711A1 (es) 2019-05-17
ZA201908466B (en) 2020-05-27
JP2019527705A (ja) 2019-10-03
MX2020013014A (es) 2021-02-22
SI3494115T1 (sl) 2021-02-26
KR102429704B1 (ko) 2022-08-04
JP7205903B2 (ja) 2023-01-17
RU2744358C2 (ru) 2021-03-05
AU2017305508A1 (en) 2019-02-07
KR102376764B1 (ko) 2022-03-18

Similar Documents

Publication Publication Date Title
LT3494115T (lt) N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
LT3788042T (lt) Bcl-2 inhibitoriai
EP4051676A4 (en) BCL-2 INHIBITORS
IL269196A (en) Novel inhibitors
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3440076T3 (da) Heterocykliske amider, der kan anvendes som proteinmodulatorer
DK3755703T3 (da) N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
DK3442947T3 (da) Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3472165T3 (da) N-(substituererede-phenyl)-sulfonamidderivater som kinasehæmmere
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
LT3464272T (lt) Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
EP3761992A4 (en) ARGINASE INHIBITORS
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3334709T3 (da) Salte af en lsd1-hæmmer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3672976T3 (da) Bcl-2-hæmmere
IL277778B (en) Bcl6 inhibitors
DK3837258T3 (da) Dimethyl amino azetidine amides as jak inhibitors
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
DK3687996T3 (da) Salte af pyrrolotriazinderivater anvendelige som tam-inhibitorer
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
EP3624804A4 (en) HISTONE DEACETYLASE INHIBITORS (HDAC)